A calm, evidence-led tour of the disorders, the therapies, the neurobiology beneath, and the long shadow of stigma.
Mental health is a state of well-being in which a person can cope with normal stresses, work productively, and contribute to community. Mental illness — diagnosable disorders of mood, thought, behavior, or development — is common: roughly 1 in 5 adults globally each year.
Modern psychiatry classifies disorders using two manuals: the American DSM-5-TR (Diagnostic and Statistical Manual, 2022 revision) and the WHO ICD-11. They are descriptive, not etiological — meaning a diagnosis names a pattern of symptoms, not its cause. Causes are typically a mix of genetic vulnerability, neurobiology, early experience, and current stressors.
Major depressive disorder (MDD) is more than sadness. The DSM-5 requires five or more of nine symptoms — including depressed mood or anhedonia — present for at least two weeks. Lifetime prevalence is ~20% in high-income countries, with women diagnosed roughly twice as often as men.
Bipolar disorder cycles between depression and either mania (Bipolar I) or hypomania (Bipolar II). Mania is not just "feeling great" — sleep collapses, judgment fails, and psychosis can appear. Lithium, discovered to stabilize mood by John Cade in 1949, remains a first-line treatment 75 years on.
| Disorder | Core feature | First-line treatment |
|---|---|---|
| Major depressive | Anhedonia, low mood ≥2 wk | SSRI (e.g. sertraline) + therapy |
| Bipolar I | Mania ≥1 wk | Lithium, valproate, quetiapine |
| Bipolar II | Hypomania + depression | Lamotrigine, lurasidone |
| Persistent depressive | Low mood ≥2 yr | SSRI + CBT |
Anxiety disorders are the most prevalent class of mental illness — affecting ~30% of adults at some point. They share a common engine: an overactive threat-detection system. Generalized anxiety disorder presents with chronic, free-floating worry; panic disorder with acute autonomic surges; phobias with focused fear; social anxiety with fear of evaluation.
The amygdala rapidly tags stimuli as threatening, triggering the hypothalamic–pituitary–adrenal (HPA) axis: cortisol rises, heart races, breathing quickens. The prefrontal cortex normally dampens this. In anxiety disorders the dampening is weak; threat signals dominate.
Post-traumatic stress disorder (PTSD) follows exposure to actual or threatened death, serious injury, or sexual violence. The DSM-5 cluster: re-experiencing (flashbacks, nightmares), avoidance, negative cognition/mood, and hyperarousal — lasting more than one month.
Roughly 6–9% of adults develop PTSD in their lifetime. Effective treatments include trauma-focused CBT, prolonged exposure therapy, EMDR (Eye Movement Desensitization and Reprocessing), and SSRIs. MDMA-assisted therapy and psilocybin show promise in trials but are not yet standard-of-care.
Felitti & Anda's 1998 study of 17,000 adults found that childhood adversity (abuse, neglect, household dysfunction) is dose-dependently linked to adult depression, addiction, suicide, heart disease, and early death. Trauma is biological, not just psychological.
Schizophrenia (lifetime prevalence ~0.5–1%) typically emerges in late adolescence or early adulthood. Symptoms divide into positive (added to normal experience: hallucinations, delusions, disorganized speech), negative (subtracted: blunted affect, avolition), and cognitive (working memory, attention).
The dominant theory invokes dopamine dysregulation — too much in mesolimbic pathways (positive symptoms), too little in mesocortical (negative). Glutamate (NMDA receptor) hypofunction is also implicated. Antipsychotics — first-generation (haloperidol) and second-generation (risperidone, olanzapine, clozapine) — are the mainstay. Clozapine remains the most effective for treatment-resistant cases despite its monitoring requirements.
Mood, satiety, sleep. SSRIs block its reuptake, raising synaptic levels — onset of effect: 4–6 weeks.
Reward, motivation, motor control. Excess in psychosis; deficit in Parkinson's.
Arousal, attention, fight-or-flight. Targeted by SNRIs and stimulants.
Major inhibitory transmitter. Benzodiazepines and alcohol potentiate its receptor.
Major excitatory transmitter. Ketamine's NMDA antagonism produces rapid antidepressant effect.
Memory, attention. Reduced in Alzheimer's; targeted by donepezil.
"The chemical-imbalance story is a useful simplification, not a complete theory. Real mood disorders involve circuits, plasticity, inflammation, and life context."
Pioneered by Aaron Beck (1960s). Identifies and reshapes maladaptive thoughts that maintain symptoms. Strong evidence for depression, anxiety, OCD, insomnia, PTSD.
Marsha Linehan, 1990s. Combines CBT with mindfulness; first-line for borderline personality disorder.
Roots in Freud; modern evidence supports its efficacy for depression and personality disorders, particularly for insight-oriented patients.
Hayes, 1980s. Emphasizes psychological flexibility and values-driven action over symptom elimination.
Gold standard for phobias, OCD, PTSD. Gradual confrontation extinguishes the fear response.
Multisystemic, family-based, and group formats add social leverage; especially useful for adolescents and addiction.
| Class | Examples | Used for |
|---|---|---|
| SSRI | fluoxetine, sertraline, escitalopram | Depression, anxiety, OCD |
| SNRI | venlafaxine, duloxetine | Depression, neuropathic pain |
| Atypical antidepressant | bupropion, mirtazapine | Depression (alt. profiles) |
| Mood stabilizer | lithium, valproate, lamotrigine | Bipolar disorder |
| Atypical antipsychotic | risperidone, olanzapine, quetiapine, aripiprazole | Schizophrenia, bipolar, adjunct depression |
| Benzodiazepine | lorazepam, alprazolam, clonazepam | Acute anxiety; short-term only |
| Stimulant | methylphenidate, amphetamine | ADHD |
Therapy at its core is a human relationship. The "therapeutic alliance" — the patient–clinician working bond — predicts outcome at least as strongly as the specific modality used.
Mental illness has been blamed on demons, weak character, bad parenting, and bad genes — and is still routinely concealed. Stigma reduces help-seeking, employment, and housing access. Public-health campaigns like Time to Change (UK) and the Bell Let's Talk movement have measurably shifted attitudes; structural changes (parity laws requiring insurance to cover mental and physical illness equally) have shifted access.
Strong evidence: CBT for anxiety/depression; SSRIs for moderate–severe depression; lithium for bipolar; antipsychotics for schizophrenia; ECT for treatment-resistant depression. Moderate evidence: ketamine, esketamine, MDMA-assisted therapy. Weaker: most "neurochemical imbalance" claims as singular causes; supplements for serious mental illness; many wellness apps.
Mental-health research is hampered by heterogeneous diagnoses, modest effect sizes, and replication failures. Treat strong claims of "cure" with skepticism, and gentle improvements as the realistic norm.
Stanford neuroscientist Andrew Huberman discusses evidence-based behaviors that support mental health, from light exposure to therapy.
Further reading: Lost Connections, Johann Hari · The Body Keeps the Score, Bessel van der Kolk · Maybe You Should Talk to Someone, Lori Gottlieb · NIMH and WHO public materials.
This deck is educational and is not a substitute for diagnosis or treatment. If you or someone you know is in crisis, contact a local emergency line; in the US, dial or text 988.